PAI
NAMS icon

Palo Alto Investors’s NewAmsterdam Pharma NAMS Stock Holding History

Palo Alto Investors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
+44,359
New +$1.46M 0.21% 43

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Palo Alto Investors's NAMS Position: Q2 2026 in Review

Palo Alto Investors opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 44,359 shares worth $1.5M. The stake represents 0.21% of the portfolio and ranks #43 among its holdings.

194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Palo Alto Investors held 44,359 shares of NewAmsterdam Pharma worth $1.5M as of Q2 2026.
  • NewAmsterdam Pharma was a new Palo Alto Investors position in Q2 2026.
  • NewAmsterdam Pharma made up 0.21% of Palo Alto Investors's portfolio in Q2 2026, its #43 holding.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.